NEW YORK, Aug. 5, 2009 (GLOBE NEWSWIRE) -- Prana Biotechnology (Nasdaq:PRAN) (ASX:PBT) today announced that it has secured a key patent protecting its clinical drug asset PBT2, with the European Patent Office issuing a notice of Decision to Grant in Europe. The patent entitled '8-Hydroxyquinoline derivatives' covers the composition of matter of selected families of 8-Hydroxyquinoline compounds, including PBT2 and the uses of such compounds for the treatment of neurological diseases, including Alzheimer's Disease and Huntington's Disease.
